FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092397815> ?p ?o ?g. }

• W3092397815 endingPage "e688" @default.
• W3092397815 startingPage "e677" @default.
• W3092397815 abstract "Background The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related to pain in patients with active rheumatoid arthritis receiving otilimab. Methods This phase 2b, dose-ranging, multicentre, placebo-controlled study was done at 64 sites across 14 countries. Patients aged 18 years or older with rheumatoid arthritis who were receiving stable methotrexate were randomly assigned (1:1:1:1:1:1) to subcutaneous placebo or otilimab 22·5 mg, 45 mg, 90 mg, 135 mg, or 180 mg, plus methotrexate, once weekly for 5 weeks, then every other week until week 50. The randomisation schedule was generated by the sponsor, and patients were assigned to treatment by interactive response technology. Randomisation was blocked (block size of six) but was not stratified. Investigators, patients, and the sponsor were blinded to treatment. An unblinded administrator prepared and administered the study drug. The primary endpoint was the proportion of patients who achieved disease activity score for 28 joints with C-reactive protein (DAS28-CRP) <2·6 at week 24. Patients who were not in the otilimab 180 mg group, without a good or moderate European League Against Rheumatism response (week 12) or with DAS28-CRP >3·2 (week 24) escaped to otilimab 180 mg. Patients who escaped were treated as non-responders in their original assigned group. Safety endpoints were incidence of adverse events and serious adverse events, infections, and pulmonary events. Efficacy and safety outcomes were assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02504671. Findings Between July 23, 2015, and Dec 29, 2017, 222 patients were randomly assigned (37 to each group). 86 (49%) of 175 escaped to otilimab 180 mg at week 12 and 57 (69%) of 83 at week 24. At week 24, the proportion of patients with DAS28-CRP <2·6 was two (5%) of 37 in the otilimab 22·5 mg group, six (16%) of 37 in the 45 mg group, seven (19%) of 37 in the 90 mg group, five (14%) of 37 in the 135 mg group, five (14%) of 37 in the 180 mg, and one (3%) of 37 in the placebo group. The largest difference was achieved with otilimab 90 mg (16·2%; odds ratio [OR] 8·39, 95% CI 0·98–72·14; p=0·053). Adverse events were reported pre-escape in 19–24 (51–65%) patients and post escape in 10–17 (40–61%) patients across otilimab dose groups and in 18 (49%) of 37 and 22 (67%) of 33 in the placebo group. The most common adverse event was nasopharyngitis: 3–9 (8–24%) in otilimab groups and one (3%) in the placebo group pre-escape and 1–3 (4–10%) in otilimab groups and seven (21%) in the placebo group post escape. Pre-escape serious adverse events were foot fracture (otilimab 45 mg); arthralgia, myocardial infarction, dizziness (otilimab 90 mg); oesophageal spasm, acute pyelonephritis (otilimab 22·5 mg), and uterine leiomyoma (otilimab 135 mg). Post-escape serious adverse events were ankle fracture (placebo) and rheumatoid arthritis (otilimab 135 mg). There were no deaths or pulmonary events of clinical concern, and rates of serious infection were low. Interpretation Otilimab plus methotrexate was well tolerated and, despite not achieving the primary endpoint of DAS28-CRP remission, there were improvements compared with placebo in disease activity scores. Of note, patients reported significant improvement in pain and physical function, supporting further clinical development of otilimab in rheumatoid arthritis. Funding GlaxoSmithKline." @default.
• W3092397815 created "2020-10-15" @default.
• W3092397815 creator A5005489241 @default.
• W3092397815 creator A5012564728 @default.
• W3092397815 creator A5016078512 @default.
• W3092397815 creator A5017346626 @default.
• W3092397815 creator A5022363575 @default.
• W3092397815 creator A5024402393 @default.
• W3092397815 creator A5025909380 @default.
• W3092397815 creator A5032346628 @default.
• W3092397815 creator A5040935737 @default.
• W3092397815 creator A5041778235 @default.
• W3092397815 creator A5057412604 @default.
• W3092397815 creator A5059124438 @default.
• W3092397815 creator A5063357547 @default.
• W3092397815 creator A5070660065 @default.
• W3092397815 creator A5086912710 @default.
• W3092397815 date "2020-11-01" @default.
• W3092397815 modified "2023-10-18" @default.
• W3092397815 title "Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study" @default.
• W3092397815 cites W1905136944 @default.
• W3092397815 cites W1976833987 @default.
• W3092397815 cites W1981274829 @default.
• W3092397815 cites W1998703243 @default.
• W3092397815 cites W2018491206 @default.
• W3092397815 cites W2079760167 @default.
• W3092397815 cites W2081734937 @default.
• W3092397815 cites W2114432397 @default.
• W3092397815 cites W2125212735 @default.
• W3092397815 cites W2128952811 @default.
• W3092397815 cites W2133541603 @default.
• W3092397815 cites W2134171514 @default.
• W3092397815 cites W2163478426 @default.
• W3092397815 cites W2167446675 @default.
• W3092397815 cites W2184655932 @default.
• W3092397815 cites W2205708478 @default.
• W3092397815 cites W2507400976 @default.
• W3092397815 cites W2566211026 @default.
• W3092397815 cites W274539098 @default.
• W3092397815 cites W2888671596 @default.
• W3092397815 cites W2937167388 @default.
• W3092397815 cites W2944290211 @default.
• W3092397815 cites W2944564829 @default.
• W3092397815 cites W2949930962 @default.
• W3092397815 cites W2964834213 @default.
• W3092397815 cites W3091939747 @default.
• W3092397815 doi "https://doi.org/10.1016/s2665-9913(20)30229-0" @default.
• W3092397815 hasPublicationYear "2020" @default.
• W3092397815 type Work @default.
• W3092397815 sameAs 3092397815 @default.
• W3092397815 citedByCount "21" @default.
• W3092397815 countsByYear W30923978152020 @default.
• W3092397815 countsByYear W30923978152021 @default.
• W3092397815 countsByYear W30923978152022 @default.
• W3092397815 countsByYear W30923978152023 @default.
• W3092397815 crossrefType "journal-article" @default.
• W3092397815 hasAuthorship W3092397815A5005489241 @default.
• W3092397815 hasAuthorship W3092397815A5012564728 @default.
• W3092397815 hasAuthorship W3092397815A5016078512 @default.
• W3092397815 hasAuthorship W3092397815A5017346626 @default.
• W3092397815 hasAuthorship W3092397815A5022363575 @default.
• W3092397815 hasAuthorship W3092397815A5024402393 @default.
• W3092397815 hasAuthorship W3092397815A5025909380 @default.
• W3092397815 hasAuthorship W3092397815A5032346628 @default.
• W3092397815 hasAuthorship W3092397815A5040935737 @default.
• W3092397815 hasAuthorship W3092397815A5041778235 @default.
• W3092397815 hasAuthorship W3092397815A5057412604 @default.
• W3092397815 hasAuthorship W3092397815A5059124438 @default.
• W3092397815 hasAuthorship W3092397815A5063357547 @default.
• W3092397815 hasAuthorship W3092397815A5070660065 @default.
• W3092397815 hasAuthorship W3092397815A5086912710 @default.
• W3092397815 hasBestOaLocation W30923978152 @default.
• W3092397815 hasConcept C126322002 @default.
• W3092397815 hasConcept C141071460 @default.
• W3092397815 hasConcept C142724271 @default.
• W3092397815 hasConcept C168563851 @default.
• W3092397815 hasConcept C197934379 @default.
• W3092397815 hasConcept C203092338 @default.
• W3092397815 hasConcept C204787440 @default.
• W3092397815 hasConcept C27081682 @default.
• W3092397815 hasConcept C2776232647 @default.
• W3092397815 hasConcept C2777489490 @default.
• W3092397815 hasConcept C2777575956 @default.
• W3092397815 hasConcept C2781059491 @default.
• W3092397815 hasConcept C71924100 @default.
• W3092397815 hasConceptScore W3092397815C126322002 @default.
• W3092397815 hasConceptScore W3092397815C141071460 @default.
• W3092397815 hasConceptScore W3092397815C142724271 @default.
• W3092397815 hasConceptScore W3092397815C168563851 @default.
• W3092397815 hasConceptScore W3092397815C197934379 @default.
• W3092397815 hasConceptScore W3092397815C203092338 @default.
• W3092397815 hasConceptScore W3092397815C204787440 @default.
• W3092397815 hasConceptScore W3092397815C27081682 @default.
• W3092397815 hasConceptScore W3092397815C2776232647 @default.
• W3092397815 hasConceptScore W3092397815C2777489490 @default.
• W3092397815 hasConceptScore W3092397815C2777575956 @default.
• W3092397815 hasConceptScore W3092397815C2781059491 @default.
• W3092397815 hasConceptScore W3092397815C71924100 @default.

• next